- Oregon Right to Repair Letter ( )
- Comment from the Federal Trade Commission on Artificial Intelligence and Copyright ( )
- Letter to Assemblymember Fahy from Sam Levine and Elizabeth Wilkins ( )
- FTC Staff Letter to Department of Health and Human Services Concerning the 21st Century Cures Act: Interoperability, Information Blocking and the ONC Health IT Certification Program Rule ( )
- Federal Trade Commission's Statement of Public Interest ( )
- Comment of the Staff of the Federal Trade Commission’s Bureau of Consumer Protection: Preliminary Draft for the NIST Privacy Framework ( )
- Comment of the Staff of the Federal Trade Commission’s Bureau of Consumer Protection Before the Consumer Product Safety Commission In the Matter of the Internet of Things and Consumer Product Hazards ( )
- FTC Staff Comment to the National Telecommunications and Information Administration Regarding the Safety Working Groups “Coordinated Vulnerability Disclosure ‘Early Stage’ Template” ( )
- FTC Staff Comment to the NTIA: The Benefits, Challenges, and Potential Roles for the Government in Fostering the Advancement of the Internet of Things ( )
- FTC Staff Comment to the Federal Communications Commission: In the Matter of Protecting the Privacy of Customers of Broadband and Other Telecommunications Services ( )
- Comment Filed by Jessica Rich on Privacy Enforcement Implications of FCC’s Proposed Set-Top Box Rulemaking ( )
- FTC Comment Before the Federal Communications Commission Concerning the National Broadband Plan ( )
- FTC Comment Before The Patent and Trademark Office regarding Changes to Practice for Continuing Applications, Requests for Continued Examination Practice, and Applications Containing Patentably Indistinct Claims ( )
- Possible Anticompetitive Barriers to E-Commerce: Contact Lenses: A Report from the Staff of the FTC ( )
- FTC Comment Before the Food and Drug Administration Concerning Applications for FDA Approval to Market a New Drug (Relating to Abbreviated New Drug Application Procedures) ( )
- FTC Staff Comment Before Food and Drug Administration Concerning 180-Day Generic Drug Exclusivity for Abbreviated New Drug Applications ( )
- FTC Staff Comment to the National Conference of Commissioners on Uniform State Laws Concerning the Uniform Computer Information Transactions Act (UCITA) ( )